(Q37454538)

20 August 2017

0 references

S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis (English)

1 reference

20 August 2017

0 references

Guo-Fang Liu

1

1 reference

20 August 2017

Dong Tang

2

1 reference

20 August 2017

Ping Li

3

1 reference

20 August 2017

Su Wang

4

1 reference

20 August 2017

Ya-Xiang Xu

5

1 reference

20 August 2017

Ai-Hua Long

6

1 reference

20 August 2017

Nian-Lan Zhou

7

1 reference

20 August 2017

Li-Li Zhang

8

1 reference

20 August 2017

Jie Chen

9

1 reference

20 August 2017

Xiao-Xing Xiang

10

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

World Journal of Gastroenterology

20 August 2017

1 reference

20 August 2017

20

1 reference

20 August 2017

1

1 reference

20 August 2017

310-318

1 reference

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

The role of S-1 in the treatment of gastric cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Global cancer statistics, 2002

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

S-1 in gastric cancer: a comprehensive review

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

23 August 2017

Cancer statistics, 2000.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Meta-analysis: formulating, evaluating, combining, and reporting

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Bias in meta-analysis detected by a simple, graphical test

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Operating characteristics of a rank correlation test for publication bias

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3886025

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

2 September 2018

1 reference

12 December 2020

Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients

1 reference

12 December 2020

Chemotherapy for gastric carcinoma: new and old options

1 reference

12 December 2020

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

12 December 2020

Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V20.I1.310

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24415887

1 reference